Author:
Lu Lifei,Wu Fan,Peng Jieqi,Wu Xiaohui,Hou Xiangqing,Zheng Youlan,Yang Huajing,Deng Zhishan,Dai Cuiqiong,Zhao Ningning,Zhou Kunning,Wan Qi,Tang Gaoying,Cui Jiangyu,Yu Shuqing,Luo Xiangwen,Yang Changli,Chen Shengtang,Ran Pixin,Zhou Yumin
Abstract
Abstract
Background
The clinical significance of the impulse oscillometry-defined small airway bronchodilator response (IOS-BDR) is not well-known. Accordingly, this study investigated the clinical characteristics of IOS-BDR and explored the association between lung function decline, acute respiratory exacerbations, and IOS-BDR.
Methods
Participants were recruited from an Early Chronic Obstructive Pulmonary Disease (ECOPD) cohort subset and were followed up for two years with visits at baseline, 12 months, and 24 months. Chronic obstructive pulmonary disease (COPD) was defined as a post-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio < 0.70. IOS-BDR was defined as meeting any one of the following criteria: an absolute change in respiratory system resistance at 5 Hz ≤ − 0.137 kPa/L/s, an absolute change in respiratory system reactance at 5 Hz ≥ 0.055 kPa/L/s, or an absolute change in reactance area ≤ − 0.390 kPa/L. The association between IOS-BDR and a decline in lung function was explored with linear mixed-effects model. The association between IOS-BDR and the risk of acute respiratory exacerbations at the two-year follow-up was analyzed with the logistic regression model.
Results
This study involved 466 participants (92 participants with IOS-BDR and 374 participants without IOS-BDR). Participants with IOS-BDR had higher COPD assessment test and modified Medical Research Council dyspnea scale scores, more severe emphysema, air trapping, and rapid decline in FVC than those without IOS-BDR over 2-year follow-up. IOS-BDR was not associated with the risk of acute respiratory exacerbations at the 2-year follow-up.
Conclusions
The participants with IOS-BDR had more respiratory symptoms, radiographic structural changes, and had an increase in decline in lung function than those without IOS-BDR.
Trial registration
Chinese Clinical Trial Registry, ChiCTR1900024643. Registered on 19 July, 2019.
Funder
the National Key Research and Development Program
the Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program
the National Natural Science Foundation of China
the Foundation of Guangzhou National Laboratory
the Clinical and Epidemiological Research Project of State Key Laboratory of Respiratory Disease
Publisher
Springer Science and Business Media LLC